Related Experiment Videos
Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome
D R Gandara1, B Leigh, E Vallieres
1Davis Cancer Center, University of California, Sacramento, USA. david.gandara@ucdmc.ucdavis.edu
Lung Cancer (Amsterdam, Netherlands)
|November 26, 1999
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
Annals of oncology : official journal of the European Society for Medical Oncology·2022
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
European journal of cancer (Oxford, England : 1990)·2018
Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.
Lung cancer (Amsterdam, Netherlands)·2026
Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials.
Lung cancer (Amsterdam, Netherlands)·2026
Reassessing surgical resection in small cell lung cancer in the multimodal treatment era.
Lung cancer (Amsterdam, Netherlands)·2026
Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC grading.
Lung cancer (Amsterdam, Netherlands)·2026
Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios.
Lung cancer (Amsterdam, Netherlands)·2026
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.
Lung cancer (Amsterdam, Netherlands)·2026
Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.
Expert review of anticancer therapy·2026
Atypical cytokine release syndrome induced by carboplatin: The first described case report.
International journal of immunopathology and pharmacology·2026
Effects of X-ray and carbon-ion beam irradiation on pathological cardiac remodeling in mice.
Journal of radiation research·2026
Applying Retrorectal Oncologic Tumor Dissection Planes to a Pelvic Tailgut Cyst.
The American surgeon·2026